Crystal Structures of Prostaglandin D2 11-Ketoreductase (AKR1C3) in Complex with the Nonsteroidal Anti-Inflammatory Drugs Flufenamic Acid and Indomethacin
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
It is becoming increasingly well established that nonsteroidal anti-inflammatory drugs (NSAID) protect against tumors of the gastrointestinal tract and that they may also protect against a variety of other tumors. These activities have been widely attributed to the inhibition of cylooxygenases (COX) and, in particular, COX-2. However, several observations have indicated that other targets may be involved. Besides targeting COX, certain NSAID also inhibit enzymes belonging to the aldo-keto reductase (AKR) family, including AKR1C3. We have demonstrated previously that overexpression of AKR1C3 acts to suppress cell differentiation and promote proliferation in myeloid cells. However, this enzyme has a broad tissue distribution and therefore represents a novel candidate for the target of the COX-independent antineoplastic actions of NSAID. Here we report on the X-ray crystal structures of AKR1C3 complexed with the NSAID indomethacin (1.8 Å resolution) or flufenamic acid (1.7 Å resolution). One molecule of indomethacin is bound in the active site, whereas flufenamic acid binds to both the active site and the β-hairpin loop, at the opposite end of the central β-barrel. Two other crystal structures (1.20 and 2.1 Å resolution) show acetate bound in the active site occupying the proposed oxyanion hole. The data underline AKR1C3 as a COX-independent target for NSAID and will provide a structural basis for the future development of new cancer therapies with reduced COX-dependent side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PENNING, T. M., BURCZYNSKI, M. E., JEZ, J. M., HUNG, C.-F., LIN, H.-K., MA, H., MOORE, M., PALACKAL, N., & RATNAM, K. (2000) · Biochemical Journal · doi:10.1042/bj3510067 · Cited by 649 · cited 4×
“5) that define the active site entrance channel and ligandbinding pockets, and there are also observed differences in the activity and substrate profiles of this family (23, 47), suggestive of structure differences that could be exploited in a drug design.”
BackgroundInfluentialPeltoketo, H., Luu-The, V, Simard, J., & Adamski, J. (1999) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0230001 · Cited by 302 · cited 1×
“Besides inhibiting COX-1 and COX-2, NSAID also inhibit members of the NAD(P)H-dependent aldo-keto reductase (AKR) family, including the human enzyme AKR1C3, also known variously as 3 -hydroxysteroid dehydrogenase type 2 (21), 17 -hydroxysteroid dehydrogenase type 5 (22), and PGD2 11-ketoreductase (23).”
BackgroundKhanna, M., Qin, K.-N., Wang, R. W., & Cheng, K.-C. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.34.20162 · Cited by 174 · cited 1×
“Besides inhibiting COX-1 and COX-2, NSAID also inhibit members of the NAD(P)H-dependent aldo-keto reductase (AKR) family, including the human enzyme AKR1C3, also known variously as 3 -hydroxysteroid dehydrogenase type 2 (21), 17 -hydroxysteroid dehydrogenase type 5 (22), and PGD2 11-ketoreductase (23).”
BackgroundHoog, S. S., Pawlowski, J. E., Alzari, P. M., Penning, T. M., & Lewis, M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.7.2517 · Cited by 137
Cited by
Cai, C., Chen, S., Ng, P., Bubley, G. J., Nelson, P. S., Mostaghel, E. A., Marck, B., Matsumoto, A. M., Simon, N. I., Wang, H., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0532 · Cited by 433
Byrns, M. C., Steckelbroeck, S., & Penning, T. M. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.09.008 · Cited by 145
AKR1C3 as a target in castrate resistant prostate cancer
Adeniji, A. O., Chen, M., & Penning, T. M. (2013) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2013.05.012 · Cited by 143
Substrate specificity and inhibitor analyses of human steroid 5β-reductase (AKR1D1)
Chen, M., Drury, J. E., & Penning, T. M. (2011) · Steroids · doi:10.1016/j.steroids.2011.01.003 · Cited by 53
Jin, Y., Duan, L., Lee, S. H., Kloosterboer, H. J., Blair, I. A., & Penning, T. M. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m809465200 · Cited by 50
Metadata
- Authors
- Lovering, A. L., Ride, J. P., Bunce, C. M., Desmond, J. C., Cummings, S. M., & White, S. A.
- Venue
- Cancer Research
- Published
- 2004-03-01
- Volume
- 64
- Issue
- 5
- Pages
- 1802-1810
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2101605468
- Cited by
- 121
- References
- 4
- FWCI
- 2.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Crystal Structures of Prostaglandin D2 11-Ketoreductase (AKR1C3) in Complex with the Nonsteroidal Anti-Inflammatory Drugs Flufenamic Acid and Indomethacin. https://app.cochat.ai/papers/10.1158/0008-5472.can-03-2847
- The paper
- Lovering, A. L., Ride, J. P., Bunce, C. M., Desmond, J. C., Cummings, S. M., & White, S. A. (2004). Crystal Structures of Prostaglandin D2 11-Ketoreductase (AKR1C3) in Complex with the Nonsteroidal Anti-Inflammatory Drugs Flufenamic Acid and Indomethacin. Cancer Research. https://doi.org/10.1158/0008-5472.can-03-2847
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.